✦ LIBER ✦

48-week efficacy and tolerability of treatment with SB-742457, a novel 5HT6 receptor antagonist, when added on to donepezil in subjects with mild-to-moderate Alzheimer's disease (AD)

✍ Scribed by Maher-Edwards, Gareth; Ascher, John; Watson, Carolyn; Zvartau-Hind, Marina; Donovan, Carly; Davies, John; Safirstein, Beth; Zanetti, Orazio; Fernandez, Manuel; Gold, Michael

Book ID: 122900912
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 54 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.09.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P4-341: Efficacy and tolerability of SB-

P4-341: Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonist, and Donepezil in subjects with mild-to-moderate Alzheimer's disease (AD)

✍ Maher-Edwards, Gareth; Dixon, Ruth; Hunter, Jackie; Gold, Michael; Hopton, Gilli 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 181 KB

O3-04-06: Efficacy and tolerability of S

O3-04-06: Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonist, in subjects with mild-to-moderate Alzheimer's disease (AD)

✍ Marina Zvartau-Hind; Gareth Maher-Edwards; Jackie Hunter; Michael Gold; Gillian 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Effects of 6-month monotherapy treatment

Effects of 6-month monotherapy treatment with the 5HT6 receptor antagonist SB 742457 or donepezil in subjects with mild-to-moderate Alzheimer's disease

✍ Maher-Edwards, Gareth; Zvartau-Hind, Marina; Davies, John; Alexander, Kurz; Schr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Effect of 6 months of monotherapy with t

Effect of 6 months of monotherapy with the 5HT6 receptor antagonist SB-742457 or donepezil in subjects with mild-to-moderate Alzheimer's disease

✍ Gareth Maher-Edwards; John Davies; Kurz Alexander; Juan Schronen; Diane Boswell; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Safety, tolerability, and preliminary ef

Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT-6 antagonist, in subjects with mild-to-moderate Alzheimer's disease: Results from a phase 2a study

✍ Claudine Brisard; Beth Safirstein; Kevin Booth; Lisa Hua; Yves Brault; Sangeeta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB